Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
J Thromb Haemost. 2015 Oct;13(10):1833-42. doi: 10.1111/jth.13071. Epub 2015 Sep 2.
Factor VIII (FVIII) levels are increased in individuals with a non-O blood group and play a role in the etiology of thrombosis. High FVIII levels have also been associated with increased all-cause mortality.
We explored whether elevated FVIII levels are associated with an increased risk of death in patients who had venous thrombosis and in individuals from the general population, and to what extent this association is causal.
We followed 2178 patients with previous venous thrombosis and 2827 age and sex-matched community controls for on average 5.5 years and measured their FVIII levels and ABO blood group.
All-cause mortality increased in a dose-response fashion with increasing percentiles of FVIII levels. In the thrombosis patients the risk was highest above the 97.5th percentile (FVIII > 199 IU dL(-1) ) with an adjusted hazard ratio (HR) of 3.1 (95% confidence interval [CI], 0.9-10.8) as compared with patients in the 25th percentile category (FVIII ≤ 85 IU dL(-1) ). The adjusted HR was 4.5 (95% CI, 1.4-14.3) in controls. Using non-O blood group as a measure of genetically elevated FVIII levels to determine a causal relationship between FVIII and death showed observed HRs of 0.99 (95% CI, 0.72-1.36) in patients and 1.25 (95% CI, 0.82-1.90) in controls.
We showed a dose-response relationship between high FVIII levels and risk of death in venous thrombosis patients and in individuals from the general population. However, environmental factors, such as chronic comorbidities and chronic inflammation, are at least in part responsible for the association between factor VIII and mortality.
非 O 血型个体的凝血因子 VIII(FVIII)水平升高,并且在血栓形成的病因学中发挥作用。高 FVIII 水平也与全因死亡率增加相关。
我们探讨了在患有静脉血栓形成的患者和一般人群中,升高的 FVIII 水平是否与死亡风险增加相关,以及这种关联在多大程度上是因果关系。
我们对 2178 例既往有静脉血栓形成的患者和 2827 例年龄和性别匹配的社区对照者进行了平均 5.5 年的随访,并测量了他们的 FVIII 水平和 ABO 血型。
全因死亡率随着 FVIII 水平百分位数的升高呈剂量反应式增加。在血栓形成患者中,风险在第 97.5 个百分位数以上(FVIII>199IU/dL)最高,调整后的危险比(HR)为 3.1(95%置信区间[CI],0.9-10.8),与第 25 个百分位数组(FVIII≤85IU/dL)的患者相比。在对照组中,调整后的 HR 为 4.5(95%CI,1.4-14.3)。使用非 O 血型作为 FVIII 水平升高的遗传标志物来确定 FVIII 与死亡之间的因果关系,在患者中观察到的 HR 为 0.99(95%CI,0.72-1.36),在对照组中为 1.25(95%CI,0.82-1.90)。
我们在静脉血栓形成患者和一般人群中显示了 FVIII 水平升高与死亡风险之间的剂量反应关系。然而,环境因素,如慢性合并症和慢性炎症,至少部分解释了 FVIII 与死亡率之间的关联。